M&A / Deals Heart drug biotech Kardigan raises $400m in upscaled IPO PharmaphorumCardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen pens $1bn deal to buy immunology biotech RayThera Related Stories M&A / Deals Biogen pens $1bn deal to buy immunology biotech RayThera pharminent June 18, 2026 M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera pharminent June 17, 2026 M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact pharminent June 17, 2026
